GleamWall
中文EN

ACAD ACADIA PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1070494 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY14.8%
TTM net income YoY38.7%
TTM EPS YoY36.8%
Revenue 3-yr CAGR23.9%
Net income 3-yr CAGR—

Margins

Gross margin90.5%
Operating margin10.2%
Net margin30.1%
FCF margin6.8%
EBITDA margin10.3%

Returns

ROE31.4%
ROA23.2%
ROIC (approx.)14.2%
Asset turnover0.77x

Leverage & solvency

Liabilities / assets22.7%
Debt / equity0.00x
Current ratio3.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.27x
Accruals ratio16.9%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$342.29M$307.96M$268.06M$283.99M$278.63M$264.57M$244.32M$259.60M
Cost of revenue$35.09M$28.32M$24.79M$26.23M$21.65M$20.73M$20.39M$21.80M
Gross profit$307.20M$279.64M$243.27M$257.76M$256.99M$243.83M$223.93M$237.80M
R&D expense$76.28M$81.56M$76.87M$84.76M$87.83M$77.95M$78.27M$100.73M
SG&A expense$159.20M$160.25M$171.02M$155.62M$133.40M$133.51M$126.37M$130.08M
Operating income$71.72M$37.84M-$4.62M$17.39M$35.76M$32.37M$19.29M$153.50M
Pretax income$80.44M$46.47M$3.98M$26.32M$44.59M$40.21M$27.78M$161.09M
Income tax$26.91M$14.97M$344,000-$247.25M-$27.18M$13.54M$8.79M$17.34M
Net income$53.52M$31.50M$3.64M$273.57M$71.78M$26.67M$18.99M$143.74M
EBITDA$72.41M$38.27M-$4.34M$17.59M$35.98M$32.59M$19.52M$153.73M
EPS (basic)0.310.180.02—0.430.160.11—
EPS (diluted)0.310.180.02—0.420.160.11—
Weighted avg. shares (diluted)175.47M172.85M172.71M—170.65M168.68M167.67M—
Balance sheet
Cash & equivalents$322.37M$384.99M$282.21M$177.69M$258.00M$253.64M$217.70M$319.59M
Short-term investments$654.08M$571.49M$569.25M$641.99M$589.02M$508.36M$463.88M$436.40M
Receivables$161.02M$150.64M$135.35M$121.46M$115.85M$107.50M$105.74M$98.74M
Inventory$106.84M$108.67M$112.29M$111.37M$105.98M$110.53M$102.97M$91.69M
Current assets$1.27B$1.22B$1.10B$1.06B$1.08B$960.55M$870.94M$938.32M
PP&E, net$18.40M$17.11M$14.65M$7.51M$3.71M$3.55M$3.50M$4.21M
Intangibles$135.48M$103.45M$106.17M$108.89M$111.61M$114.34M$117.06M$119.78M
Total assets$1.79B$1.74B$1.61B$1.56B$1.33B$1.23B$1.13B$1.19B
Current liabilities$332.22M$361.44M$305.52M$277.11M$356.58M$330.02M$302.53M$394.87M
Total liabilities$406.66M$436.29M$357.16M$336.81M$413.50M$403.17M$367.13M$454.96M
Shareholders' equity$1.39B$1.31B$1.25B$1.23B$917.27M$822.38M$765.24M$732.79M
Shares outstanding172.79M172.13M171.09M170.31M169.15M168.61M167.12M166.71M
Cash flow statement
Operating cash flow$11.50M$100.78M$33.98M-$48.73M$74.29M$63.96M$20.32M$40.38M
Capital expenditure$1.24M$5.09M$5.21M$4.00M$388,000$297,000$0$453,000
Free cash flow$10.26M$95.69M$28.77M-$52.74M$73.90M$63.66M$20.32M$39.93M
Investing cash flow-$86.15M-$8.53M$66.28M-$55.87M-$79.35M-$43.29M-$124.05M$122.15M
Financing cash flow$11.87M$10.49M$4.23M$22.67M$9.42M$15.96M$1.84M$1.97M
Depreciation & amortization$688,000$434,000$271,000$202,000$227,000$213,000$229,000$226,000
Stock-based compensation$17.45M$16.94M$14.70M$13.23M$13.18M$14.34M$11.38M$10.45M

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.